| Date | Title | Description |
| 03.03.2025 | Circio´s leading position in circular RNA therapeutics highlighted by continued broad coverage in international life science industry media | Circio´s leading position in circular RNA therapeutics highlighted by continued broad coverage in international life science industry media
Mon, Mar 03, 2025 07:00 CET Report this content
More than 50 articles and interviews featuring Circi... |
| 16.01.2025 | BioWorld by Clarivate Releases Comprehensive 2024 Year in Review | Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year
LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, ha... |
| 21.11.2024 | BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment in New Special Series | New seven-part series explores disparities in care, funding and innovation impacting half the world's population
LONDON, Nov. 21, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transforma... |
| 25.06.2024 | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media
Tue, Jun 25, 2024 07:00 CET Report this content
Circio´s position as a pioneering player in the rapidly... |
| 08.05.2023 | How to Ensure Quality and Reliability for At-Home Lab Tests | A robust business model prioritizing quality at every step of the process is central to any successful medical device company. History has shown that a critical point of failure in many medical device companies is when quality is not at the... |
| 17.04.2023 | Complement Therapeutics closes $79M A round for gene therapy in geographic atrophy | Complement Therapeutics closes $79M A round for gene therapy in geographic atrophy
BioWorld | By Cormac Sheridan
Complement Therapeutics GmbH raised €72 million (US$79.4 million) in a series A round to move into the clinic a novel gene ther... |
| 10.01.2023 | Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report | Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions
Promising therapeutic developments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and brea... |
| 12.12.2022 | Digital health news, funding round up in the prior week; December 12, 2022 | Apogee Therapeutics raised $149M; Palantir renewed its partnered with the CDC; Ubie raised $19M
Top Health News
The America’s Health Rankings 2022 Annual Report from the United Health Foundation found that the premature death rate increased... |
| 25.04.2022 | Cambridge Innovations raises £225M fund amid high interest in university spinouts | Cambridge Innovations raises £225M fund amid high interest in university spinouts
BioWorld article | By Nuala Moran
Cambridge Innovation Capital (CIC) has closed its oversubscribed Fund II at £225 million (US$287 million) and is moving from... |
| 15.03.2022 | Egg Medical hatches $13M VC funding |
March 4, 2022
By Annette Boyle
Egg Medical Inc. secured a $13 million investment from TVM Capital Life Science to solve the Humpty-Dumpty problem that plagues interventional cardiology – the scattering of radiation during X-ray guided p... |
| 09.03.2022 | Sense Biodetection sets sights on Europe after CE mark approval | Sense Biodetection sets sights on Europe after CE mark approval
BioWorld article | By Catherine Longworth
Sense Biodetection (Sense), is preparing to launch a new rapid, disposable, point-of-care molecular diagnostic test for COVID-19 in Eu... |
| 07.02.2022 | Clarivate Identifies Seven Medtech Trends to Watch in 2022 | Ongoing recovery from COVID-19 causing renewed pressures on procedure volumes and less urgent interventions
Report finds innovation, healthcare decentralization and mergers & acquisitions among key factors set to impact medtech markets ... |
| 23.08.2021 | Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out | Finding a functional cure to HIV is one of the biggest challenges in modern medicine, a task made so much tougher because of the virus’s ability to incorporate itself permanently into a host’s genome.
But Diaccurate SAB, of Paris, thinks i... |
| 10.02.2021 | Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada | Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people are unaware of Canadian role in this industry. However, se... |
| 12.01.2021 | QAD : Manufacturers Adapt to Protect Frontline Workers Against COVID-19 | Whew…2020 is behind us. That means it allgets easier now, right?
Not exactly. But in truth, it wasn't all bad. Challenging times often highlight the best in people. We found stories from around the globe of companies that rolled up their sl... |
| 20.12.2020 | Bringing Routine Covid-19 Testing Into The Home | Detect rapid molecular isothermal systemDetect |
| 21.09.2020 | Evolution Of The Biotech IPO Markets From Busted To Booming | getty |
| 08.09.2020 | Celltrion to begin mass producing antibody treatment before getting approval | In the race for something — anything — to rein in the pandemic, Celltrion says it will begin mass-producing its potential Covid-19 antibody treatment this month. The Incheon, South Korea-based company hopes to snag emerge... |
| 23.06.2020 | Corporate innovation weekly: the rise of hydrogen | Automotive Battery breakthroughs
Volkswagen invested a further $200m into QuantumScape, a US startup developing solid-state batteries. Volkswagen had already invested $100m in the company, and owned a 5% stake, but is now making a bigger be... |
| 07.04.2020 | Corporate innovation weekly: kidney research on hold, home delivery boom, rethinking transport | Computing Face-off
Microsoft’s M12 investment arm is divesting its stake in Israeli facial recognition company AnyVision. M12 had received a lot of criticism for its investment which was seen as in conflict with its own ethical principles a... |
| 11.03.2020 | AI is a 'potent weapon’ for fighting COVID-19 | COVID-19 might be incurable as yet, but humans have some potent weapons in our own arsenal, including artificial intelligence (AI) and high-performance computing (HPC).
Here are ten examples of how AI and HPC are helping the fight against t... |
| 05.03.2020 | Consolidation in fintech: why it's happening and what it means for the space | With Visa buying Plaid and Intuit buying Credit Karma, fintech M&A is on the rise
[Editor's note: Future of Behavioral and Mental Health with BetterHelp, Headspace, Ginger.io, Providence Hospitals, UnitedHealthcare Optum, Khosla Venture... |
| 16.01.2020 | Daily funding roundup - January 16th, 2020 | Pawlicy Advisor raised $1M; Arpeggio Bio closed $3.2M; Gentem landed $3.7M; Loliware secured $5.9M
Copilot: Copilot’s personal finance-tracking app invites users to load their financial data, then create custom categories for transactions a... |
| 05.10.2018 | European biotech funding on track for record year | The European biotech sector is on track to break its annual funding record, according to BioWorld. After a big third quarter, the total for the first nine months of the year stands at $6.3 billion, putting the region on course to clear the ... |
| 05.10.2018 | European biotech funding on track for record year | The European biotech sector is on track to break its annual funding record, according to BioWorld. After a big third quarter, the total for the first nine months of the year stands at $6.3 billion, putting the region on course to clear the ... |
| 04.10.2018 | Natalie Sacks lands at Harpoon after jumping ship at Aduro; European biotech financings surge | Natalie Sacks
→ We now know where Natalie Sacks was headed after jumping ship at Aduro $ADRO.
The chief medical officer changed hats but kept the same job, joining South San Francisco-based Harpoon Therapeutics, which has b... |
| 27.01.2017 | Ouch: Eli Lilly is walking away from Adocia deal and its ultra-fast insulin — for the second time | A little more than two years ago, Eli Lilly admitted it had made a big mistake in dumping Adocia (Paris:ADOC) and their pact on the biotech’s ultra-fast-acting insulin formulation, Biochaperone Lispro. That original deal wa... |
| 27.01.2017 | Everyone everywhere could only dream of a customer like this | By design, those quotes from customers are planned and canned.
So it was quite a departure from the ordinary to meet Robert Huizinga, vice president of clinical affairs, Aurinia Pharmaceuticals during the J.P. Morgan Healthcare Conference i... |
| 22.12.2016 | Aurinia rallies $25M for lupus nephritis drug | Back in October, Aurinia’s stock surged 10 percent in a matter of minutes, based on speculation that it would soon be acquired. Nothing substantial has been reported since and the company now has a clear financial path to get its lead drug ... |
| 11.08.2016 | Protocols: Infinity hunts up a buyer for its disappointing cancer drug duvelisib; Is Northwest Bio finally broke? | AbbVie’s decision to abruptly pull out of its partnership with Infinity on duvelisib largely wrecked the company’s hopes to finally make it big after repeated setbacks over the years. But Infinity CEO Adelene Perkin... |
| 18.12.2015 | Pharmalot, Pharmalittle: Glaxo acquires HIV drugs, Gilead gets rights to arthritis treatment | And so, another working week will soon draw to a close. Not a moment too soon, yes? After all, this has been a rather busy few days. In any event, this is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is ... |
| 15.01.2015 | #JPM15 Day 3 Buzz: We’ve captured the mood at JP Morgan – and that mood is oh so good | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| 09.09.2014 | “Deep sequencing” finds hidden causes of brain disorders | New methods can find mutations that strike just 1 in 10 cells in a sample.
By Nancy Fliesler
It’s become clear that our DNA is far from identical from cell to cell and that disease-causing mutations can happen in some of our cells and not o... |
| 04.11.2013 | Jim Blair’s Early Days with Amgen to New ‘Domain’ | |
| 10.10.2013 | San Diego Life Sciences Roundup: Tandem Diabetes, Ligand, and More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The IPO market for life sciences startups in San Diego and elsewhere remains hot, and diabetes device maker Tandem Diabetes Care joined the local parade of IPOs. We’ve got the... |
| 31.07.2013 | Why Deborah Dunsire’s Unusual Bet on Alzheimer’s Makes Sense | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Just because a biotech company has landed a high-profile chief executive, does that mean its product is going to work? I’ve been asking myself that question in the wake of the... |
| 10.04.2013 | RNAi therapeutics company starts up in San Diego with $580K | That’s a pretty big task, though. RNAi has been thought to harness potential in treating cancer and other chronic conditions caused by mutated genes such as HIV, hepatitis C and macular degeneration, but researchers have struggled to turn t... |
| 11.01.2013 | Who are the top-earning R&D executives in biotech? | The top five earners, ranked by total compensation, in 2011 were:
George Yancopoulos, founding scientist, president and chief scientific officer, Regeneron Pharmaceuticals, $2.6 million (salary = $653,000)
Roger Perlmutter, former executive... |
| 11.06.2009 | Sans IPO, Bayhill secures $350M in Genentech licensing deal | Months after giving up on its IPO hopes last year — when the market was especially brutal for lifescience companies — Bayhill Therapeutics has landed a licensing deal worth $25 million in upfront cash and equity with Genentech. It could bri... |
| 27.11.2007 | Cancer-drug biotech Agensys sells to Astellas for $387M — but is it a pig in a poke? | Yet another biotech has succumbed to Big Pharma’s deep-pocketed blandishments. Agensys, a decade-old Santa Monica, Calif., biotech with an early-stage pipeline, just agreed to sell itself to Japan’s Astellas Pharma for $387 million in cash.... |
| 21.08.2007 | Life sciences briefing: Tuesday, Aug. 21, 2007 | (UPDATED at 7:40pm PT: See below.)
Featured companies: Adnexus Therapeutics, BioForm Medical, Confirma, Cardiovascular Systems, Mirabilis Medica, Neuromed Pharmaceuticals, PlaCor, Seno Medical Instruments, Vibrynt
BioForm Medical files $115... |
| 26.06.2007 | Ceregene: Catching an updraft in gene therapy | (UPDATED: See below.)
Ceregene, a San Diego biotech at work on a gene therapy for Parkinson’s disease, has so far raised $28 million in a third funding round and last week struck a development partnership with Genzyme that resulted in a $25... |
| - | The Meta AI mafia: Meet 12 artificial intelligence researchers and engineers who quit Meta for hot startups in everything from predictive medicine to careers | Anna Buldakova, Eric Steinberger, and Anna Susmeji Anna Buldakova/ClimateScience/Anna Susmeji This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Meta's AI Research (FAIR) has been a breeding... |
| - | Everyone everywhere could only dream of a customer like this | In the business world, customer testimonials are gold especially for young startups hoping to open doors and grow.
They typically appear as one sentence kudos on the startup’s or business’s website or in press releases blessed by the market... |
| - | #JPM15 Day 3 Buzz: We’ve captured the mood at JP Morgan – and that mood is oh so good | Someone said it: “We’re not limited by capital.”
FierceBiotech on Wednesday delivered the first big verdict on the “mood” of the JP Morgan Healthcare Conference – based largely on its executive breakfast held this week in San Francisco. The... |
| - | Who are the top-earning R&D executives in biotech? | As biotech R&D spending grows, and a steady stream of biotech products continues to win regulatory approval, R&D executives at the companies commercializing these drugs have been rising accordingly.
In a new analysis published in Na... |
| - | Aurinia rallies $25M for lupus nephritis drug | Move right along. There’s no acquisition here — for now.
Canadian biotech Aurinia Pharmaceuticals announced Thursday a new $25 million financing round to power its upcoming Phase 3 trial for lupus nephritis. The money was raised through an ... |
| - | RNAi therapeutics company starts up in San Diego with $580K | Since Craig C. Mello and Andrew Fire published a paper in Nature on the gene-silencing effect of RNA interference in 1998 (for which they won a Nobel Prize in 2006), scientists have been working on clinical applications for the technique, w... |
